
TNF antagonists unexpectedly downregulate systemic IL-1β by inhibiting noncanonical inflammasome activation in patients with psoriasis. Given the known involvement of IL-1β in the pathogenesis of psoriasis skin manifestations and associated comorbidities, the findings of Verma et al. (2021) highlight a potential added benefit of targeting TNF in psoriasis.
Like
Save
Share